The 2024 New Drug Founders’ Beijing Autumn Forum Concluded Successfully

October 2024 – The New Drug Founders’ Beijing Autumn Forum, co-hosted by the International Center for Science & Technology Innovation, successfully concluded on October 24, 2024. The event brought together top industry leaders, investment experts, and scientific pioneers from Beijing and across the country. Attendees engaged in vibrant and insightful discussions on key topics such as emerging trends in policy and regulation, the role of clinical and scientific resources in industrial advancement, and recent innovations in central nervous system (CNS) therapies.

A dedicated roundtable on Innovative Practices in CNS Therapiesfeatured:

• Dr. Tinghe Wu, CEO of P.S.K.      Biosciences

• Dr. Yongjie Zhuang, CEO of KCI      BioTech

• Dr. Jun Wei, CEO of iRegene

• Dr. Yuqiang Wang, CEO of      Magpie Pharmaceuticals

Exosomes as a Next-Generation Delivery Platform

Dr. Tinghe Wu highlighted the unprecedented opportunity for exosomes as drug delivery vehicles. In nucleic acid therapeutics, where lipid nanoparticles (LNPs) face targeting limitations, exosomes represent a promising alternative for precise and effective delivery.

CMC Breakthroughs in Nucleic Acid Loading

P.S.K. Biosciences has achieved a key breakthrough in CMC (Chemistry, Manufacturing, and Controls) processes for nucleic acid encapsulation. By implementing an intracellular loading approach, the company has overcome industry bottlenecks in scalable production while significantly improving loading efficiency.

Progress in MSC-Exosome Therapeutics

With BLA applications already submitted for overseas MSC-exosome pipelines, the “Exosome Drug Era” is on the horizon. P.S.K. Bio has developed a subdivided library of MSC-exosome subgroups targeting early indications such as pulmonary fibrosis, thin endometrium repair, and inflammatory bowel disease. Several candidates have entered IIT (Investigator-Initiated Trial) studies, with the first cohort of patients showing significant clinical improvement. In neurological indications, pharmacodynamic data have also been highly encouraging.